A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK),
immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF
bispecific antibody, as a single agent in adult subjects with advanced solid tumor
malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the
maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK112 as a single agent,
and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will
characterize treatment of AK112 as a single agent at the MTD or RP2D.